MSCI vs PLX · P/E 37, rev $1.72B vs P/E 31, rev $53.6M
MSCI Inc (MSCI) versus Protalix Biotherapeutics Inc (PLX) — a side-by-side from cached financials, not a winner call.
MSCI Inc (MSCI) is a financial data & stock exchanges company listed on US.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
Latest reported MSCI revenue for 2026-06-30 was $1.72B. Net income was $748.0M. MSCI currently screens at market cap $46.82B and trailing P/E 36.8.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
MSCI currently screens at market cap $46.82B and trailing P/E 36.8. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Not investment advice. Open the MSCI and PLX stock pages for the full models.
Not investment advice.